Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A third mode of integrin antagonism.

Terence A Kelly1

  • 1Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877, USA.

Immunity
|September 23, 2003
PubMed
Summary

Researchers discovered the I-like domain regulates Leukocyte Function-associated Antigen-1 (LFA-1) allosterically. This finding offers new strategies for targeting LFA-1 and similar integrins in drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The discovery of thienopyridine analogues as potent IkappaB kinase beta inhibitors. Part II.

Bioorganic & medicinal chemistry letters·2009
Same author

Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.

Molecular cell·2007
Same author

Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.

Journal of medicinal chemistry·2006
Same author

An orally active, primate selective antagonist of LFA-1 inhibits delayed-type hypersensitivity in a humanized-mouse model.

European journal of pharmacology·2006
Same author

Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-alpha]imidazol-2-one derivatives.

Journal of medicinal chemistry·2004
Same author

Small molecule LFA-1 antagonists compete with an anti-LFA-1 monoclonal antibody for binding to the CD11a I domain: development of a flow-cytometry-based receptor occupancy assay.

Journal of immunological methods·2003

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • Leukocyte Function-associated Antigen-1 (LFA-1) is a key integrin involved in immune cell adhesion and signaling.
  • Understanding the allosteric regulation of LFA-1 is crucial for developing targeted therapies.

Discussion:

  • The study biochemically dissected conformational changes within LFA-1.
  • A novel role for the I-like domain in allosteric regulation was identified.

Key Insights:

  • The I-like domain directly influences LFA-1 function and downstream signaling pathways.
  • This provides a mechanistic basis for LFA-1 antagonism.

Outlook:

  • This research opens new therapeutic avenues for targeting LFA-1.
  • The findings may extend to other I-domain containing integrins, broadening drug target potential.

Related Experiment Videos